Mizuho comments on Quest, LabCorp after Medicare rate proposal

Preliminary CMS 2027 laboratory reimbursement rates imply an average reduction of about 16% versus 2026, with cuts concentrated in esoteric testing and proprietary laboratory analysis rates down 2.4%. Labcorp's 2026 investor-day outlook already assumes an approximately $100 million first-year PAMA headwind to revenue and earnings, while Quest's 7%-9% adjusted-EPS growth target assumes PAMA cuts. Mizuho expects bipartisan congressional support could again delay the cuts pending a legislative fix, partially mitigating the risk for Quest Diagnostics and Labcorp.

Analysis

The key investable distinction is not the headline reimbursement cut but each company’s mix of routine versus specialty testing, fixed-cost absorption, and ability to redirect volume through hospital outreach and commercial channels. DGX’s larger scale and recent execution momentum should make the absolute reimbursement pressure more manageable, while LH’s explicitly modeled first-year profit headwind creates a cleaner estimate-risk setup if the final schedule is not softened. Smaller specialty and independent labs with concentrated esoteric-test exposure could face a more severe margin squeeze, potentially creating acquisition opportunities for DGX and LH over the next 6-18 months.

The market is likely to treat a legislative delay as a full resolution, but a delay only defers the reimbursement reset and preserves uncertainty around 2028 earnings power. That matters more for DGX after its strong rerating: even if 2027 cash-flow impact is postponed, investors may begin discounting a lower terminal margin and lower multiple once the final schedule establishes the new reference point. Near term, the November final-rate release is the principal catalyst; the critical missing diligence is test-code-level exposure, Medicare revenue mix, and whether management’s offsets represent pricing, cost actions, or volume assumptions.

A contrarian outcome is that final rates or Congressional action create a relief rally in both names, particularly LH, where the embedded headwind appears more visible. That rally should be viewed as tactical unless management demonstrates that commercial pricing and mix can permanently offset the reimbursement reset without sacrificing volume. The thesis is falsified by a material legislative extension before final rates, a substantially smaller final cut, or 2027 guidance showing no incremental margin pressure versus current long-term targets.

Key Decisions for Investors

• Initiate a 1-3 month relative-value position: long DGX / short LH in equal dollar amounts, sized modestly ahead of the November final-rate release. DGX offers better downside insulation from scale and execution, while LH has clearer earnings-estimate risk; exit if final rates are materially softened or LH quantifies offsets sufficient to neutralize the first-year profit impact.
• Do not add outright DGX exposure into strength until management discloses code-level reimbursement sensitivity in its next earnings materials. A relief rally on a delay is likely to be multiple-driven rather than a durable earnings upgrade; use any move toward the upper end of sell-side targets to reduce exposure rather than chase.
• Place an alert on specialty-diagnostics peers NEO, GH, and NTRA for reimbursement disclosures and Medicare-mix commentary over the next quarter. These are not recommendations without test-code exposure data, but adverse read-through could produce larger earnings revisions than for the national labs because specialized assay economics have less room to absorb price resets.
• For existing LH longs, consider short-dated downside protection through November rather than exiting solely on preliminary rates. The asymmetric risk is a final schedule that validates the modeled headwind without a legislative delay; a Congressional extension is the principal upside catalyst for the hedge.